LEO 158968

LEO 158968 is a monoclonal antibody developed by LEO Pharma for the treatment of inflammatory diseases, including anti-inflammatory skin disorders and gout flares. It is administered via intravenous or subcutaneous injection. The drug is designed to block signaling pathways of three interleukin-1 (IL-1) family members, which play important roles in inflammatory and immune responses. As a new molecular entity, its precise mechanism of action has not been fully defined but it targets key mediators involved in inflammation. Clinical development has reached Phase 1 trials for pain, skin disorders, and gout flares[1][2][6][7].

Other names

anti-interleukin-1 receptor accessory protein antibodyanti-interleukin1 receptor accessory protein antibodyanti-interleukin 1 receptor accessory protein antibodyanti-IL-1RAcP antibodyanti-IL1RAcP antibodyanti-IL 1RAcP antibody